Novartis/QLT Visudyne Medicare Coverage Expansion Awaits More Data
The Centers for Medicare & Medicaid Services will ask for unpublished information from a peer-reviewed study of Novartis/QLT's Visudyne (verteporfin) for age-related macular degeneration before it expands coverage to off-label indications
More from Archive
More from Pink Sheet
• By
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
• By
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
• By
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.